Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2011 Results
Date:8/4/2011

ROCKVILLE, Md., Aug. 4, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the second quarter and six months ended June 30, 2011.

"We are pleased with our progress towards our vision of building a CNS specialty pharmaceutical company.  Fanapt® scripts in the U.S. continued to grow, and we have made advances towards the globalization of the franchise.  We are excited about the prospects of our tasimelteon programs in both Non-24 and major depression, which are currently underway," said Mihael Polymeropoulos, M.D., President and Chief Executive Officer.

Key Highlights:

  • Vanda recorded second quarter 2011 revenue of $7.4 million including royalties of $0.8 million. Second quarter sales of Fanapt® as reported by Novartis included a $2.7 million cumulative adjustment to gross to net sales reserves that resulted in approximately $270 thousand less in royalties to Vanda in the period.
  • Fanapt® prescriptions, as reported by IMS, reached 30,000 in the second quarter of 2011.  This represents a 17% increase over first quarter 2011 prescriptions.  
  • On July 22, 2011, the European Medicines Agency (EMA) notified Vanda that it had accepted for evaluation the Marketing Authorization Application (MAA) for oral iloperidone tablets.
  • Vanda announced commercialization agreements for two Latin American markets.  On July 11, 2011, Vanda entered into an exclusive license agreement with Probiomed S.A. de C.V. (Probiomed) for the commercialization of Fanapt® in Mexico.   On August 1, 2011, Vanda entered into an exclusive license agreement with Biotoscana Farma S.A. (Biotoscana
    '/>"/>

  • SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
    2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
    3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
    4. Vanda Presents Phase III Iloperidone Efficacy Data
    5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
    6. Vanda Pharmaceuticals Provides Update on Iloperidone
    7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
    8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
    9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
    10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
    11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/15/2014)... and HERZLIYA PITUACH, Israel , ... (NASDAQ: IMNP ) announced today that its Board ... Board succeeding Dr. Daniel Teper who continues as ... member of Immune,s Board of Directors since 2013. ... am delighted to represent the interest of shareholders and to ...
    (Date:12/15/2014)... N.Y. , Dec. 15, 2014 As ... SPL (Structured Product Labeling) markup language standard, content teams ... understanding and skills to work with the standard. Starting ... series of three webinars on the benefits and the ... one-hour webinars will be facilitated by Howard Shatz ...
    (Date:12/14/2014)... 2014  ChartSpan, a consumer platform for patients managing ... iPad medical app in the United States ... ChartSpan is an iPhone and iPad ... and send electronic healthcare records. The product was built ... of waiting for the healthcare system to deliver on ...
    Breaking Medicine Technology:Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3ChartSpan Becomes The Most Downloaded Medical App in America 2ChartSpan Becomes The Most Downloaded Medical App in America 3
    ... ST. LOUIS, March 14, 2011 Members served by Express ... pharmacy benefits account on their smart phones using a new ... Members can download the Express Rx app from ... including those on BlackBerry devices, can access the mobile-optimized website ...
    ... Streamline Health Solutions, Inc. (Nasdaq: STRM ... for hospitals, announced today that Rick Leach has been ... March 14, 2011. With more than 20 years of ... an extensive background in developing and marketing healthcare information ...
    Cached Medicine Technology:New Application Offers Express Scripts Members Convenient Account Access Across a Broad Range of Mobile Phone Platforms 2Streamline Health Appoints Rick Leach as Senior Vice President and Chief Marketing Officer 2Streamline Health Appoints Rick Leach as Senior Vice President and Chief Marketing Officer 3Streamline Health Appoints Rick Leach as Senior Vice President and Chief Marketing Officer 4
    (Date:12/17/2014)... In its comprehensive analysis of medical ... Claim Review division have recently identified out-of-network and medical ... savings are achieved on behalf of employer-clients. , ... in savings to Argus each year, with a total ... by Tom Doney, Cypress president and CEO, these in-depth ...
    (Date:12/17/2014)... Mamaroneck, NY (PRWEB) December 17, 2014 ... man who recently brought videos of MIT economist and ... and best-selling author James O’Keefe conducted the interview, which ... “Rich” stated that there was intentional mislabeling in the ... agenda in the bill: A two-hundred-and-fifty billion dollar per ...
    (Date:12/17/2014)... Dec. 16, 2014 (HealthDay News) -- Expectant parents should ... and Drug Administration recommends. Use of ultrasound imaging ... is not entirely risk-free, the agency warns. ... harm due to ultrasound imaging and heartbeat monitors, prudent ... is important," Shahram Vaezy, an FDA biomedical engineer, said ...
    (Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, ... approaching, a new study reveals that states that routinely perform ... drivers on their roads. The finding suggests that states ... to deter inebriated revelers from getting behind the wheel in ... passed regarding drinking and driving," said study lead author James ...
    (Date:12/15/2014)... OR (PRWEB) December 15, 2014 A ... by United States women as impacting skin health and ... “Four C’s of skin care.” Water and health advocate ... in a recent article describing the survey and the ... every item in every category discussed would benefit from ...
    Breaking Medicine News(10 mins):Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3
    ... incidence of Alzheimer's disease nationwide, both the New York ... passed a resolution aimed at raising awareness of the ... this brain disorder. ,The resolution declared November ... 2007 as Memory Screening Day in New York State. ...
    ... export of herbal products and medicines has the potential to ... with the creation of exclusive export promotion zones (EPZ) ... exports can be accelerated with the setting up of EPZs ... a rate of over 25 percent in countries like the ...
    ... at the 61st Annual Meeting of the Society ... Corporation, announced the worldwide launch of the Cordis ... in angioplasty procedures for patients with carotid and ... unique high-pressure expansion and low profile .014 inch ...
    ... among asylum seekers in Denmark has proportionally tripled since 2001 ... a study published Thursday . ,Sixty-seven asylum seekers ... percent of the total -- tried to end their lives ... to Help Refugees said. ,That contrasted with the ...
    ... Titan, a TATA company, is in negotiations with Prof Vijay ... to the University of Arkansas, to start production of ... deal is yet to be finalized. ,Varadan holds ... and Neuro- Electronics, Sensors and Systems; High Density Electronics Center ...
    ... Project (MVP) today released new data on the performance ... suggesting that the new vaccine-- expected to sell initially ... effective in protecting African children and their communities than ... ,MVP, a partnership between the World Health ...
    Cached Medicine News:Health News:New York Legislature Highlights for Awareness of Alzheimer's Disease 2Health News:New York Legislature Highlights for Awareness of Alzheimer's Disease 3Health News:Export of Herbal Products to Reach Rs.120 Billion by 2012: Study 2Health News:New Balloon Catheter Available Worldwide for Carotid and Renal Angioplasty 2Health News:Titan may Produce Glucose Watches Soon 2Health News:Improved Meningitis Vaccine for Africa Expected to End Deadly Scourge 2Health News:Improved Meningitis Vaccine for Africa Expected to End Deadly Scourge 3
    ... Forms strong flexible gels for ... clarifier: mixture of wide range ... water 10 mg/mL, clear, faintly ... molecular biology MP: 90 °C ...
    Inquire...
    Inquire...
    ... Melt), A low temperature agarose for ... , Optimal for in-gel restriction digestion/ligation and ... very manageable clear gel that provides excellent ... approximately 65°C and remains fluid at 37°C ...
    Medicine Products: